Company intelligence / Profile preview

Caring

Ownership: Private
Development stage: Preclinical

Overview

Caring Cross develops and enables point-of-care manufacturing of advanced therapies—including CAR-T and gene therapies—for leukemia, lymphoma, HIV, and sickle cell disease. Their focus is on making these treatments affordable and accessible by working directly with hospitals to manufacture products at the site of care. No published pivotal clinical results are available yet.

Therapeutic areas: OncologyHematologyInfectious Diseases
Modalities: CAR-T cell therapyGene therapyCell therapy
Industry: Biotech

Partnerships

Diverse network of academic institutions and organizations

Beyond the preview

Go deeper on Caring.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Caring.

Explore the full profile